SANTA CLARA, Calif.--(BUSINESS WIRE)--March 8, 2006--Affymetrix Inc. (Nasdaq:AFFX) announced today that Korea’s National Institute of Health (NIH) and Center for Disease Control and Prevention will use the Affymetrix GeneChip(R) Human Mapping 500K Array Set for a series of groundbreaking genome-wide association studies in critical disease areas, including diabetes, hypertension, asthma and metabolic syndrome.
